Pharma Focus Asia
KP - Choose our fully recyclable blister films

Adagrasib Discovered for the Treatment of Advanced Non-Small Cell Lung Cancer

Mirati Therapeutics discovered novel therapy, Adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harbouring the KRASG12C Mutation.

Adagrasib is an investigational, selective and oral small-molecule inhibitor of KRASG12C which is developed to support target inhibition, as KRASG12C protein regenerates every 24-48 hours.

In several clinical trials, Adagrasib is currently being evaluated in combination with other anti-cancer therapies with strong scientific rationale for patients with advanced solid tumors.

Lung cancer is the most common type of cancer reaching 2.21 million new cases and 1.8 million deaths globally. Among lung cancers, nearly 85 percent cases result in non-small cell lung cancer (NSCLC) and about 15 percent cases result in small cell lung cancer (SCLC).

KRASG12C is the most common mutation found in non-small cell lung cancer (NSCLC), found among 14 percent of patients with lung adenocarcinoma.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024